Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #SCIEX--SCIEX presents the ZenoTOF 7600 system, a new accurate mass LC-MS/MS instrument that features the proprietary Zeno trap and EAD fragmentation.

SCIEX Presents New Accurate Mass Instrument, The ZenoTOF 7600 System

Danaher Corporation (NYSE: DHR) has agreed to acquire privately-held Aldevron for a cash purchase price of approximately $9.6 billion. Danaher expects to finance the acquisition using cash on hand or proceeds from the issuance of commercial paper.

Danaher Scoops Up Aldevron In $9.6B Deal

WASHINGTON, June 17, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced today that Danaher has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion. Danaher expects to finance the acquisition using cash on hand and/or proceeds from the issuance of commercial paper.

Danaher To Acquire Aldevron

FedEx

NVIDIA

Sherwin-Williams

Target

We have narrowed down our search to five corporate bigwigs that have provided better returns than the S&P 500 Index in the past three months. These are: FDX, SHW, DHR, TGt and NVDA.

5 Picks as Inflation is Transitory and Tapering Is Not in View

Lowe's

Perficient

Rollins

The Dow Jones ticked up 20 points, the S&P 500 rose 0.1%, and the Nasdaq gained 0.2%. Make the most of today's market with the Top Buys from Q.ai's artificial intelligence.

Artificial Intelligence Identifies Danaher Corp Among Today's Top Buys

1-800-FLOWERS.COM

Navient

Polaris

1800 FLOWERS.COM (FLWS), Polaris (PII) & Danaher (DHR) are some of the top stocks that have striking earnings growth and positive estimate revisions at present.

5 of the Best Stocks to Invest in for Superb Earnings Growth

Danaher (DHR) possesses solid growth attributes, which could help it handily outperform the market.

Danaher (DHR) is an Incredible Growth Stock: 3 Reasons Why

MarineMax

Suburban Propane Partners

Toronto-Dominion Bank

Titan Machinery

To protect one's portfolio from suffering huge losses, investors mostly choose stocks that bear low leverage. You may buy HZO, TITN, SPH, DHR and TD.

Choose These 5 Low Leverage Stocks to Keep Your Portfolio Safe

Danaher (DHR), with an 11% rise in shares in the past three months, gains from solid product offerings, the pandemic-induced demand and focus on innovation. Inorganic activities too have been aiding.

Danaher (DHR) Shares Gain 11% in 3 Months: What's Driving It?

WASHINGTON, June 7, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Goldman Sachs Global Healthcare Conference on Tuesday, June 8, 2021 at 2:10 p.m. ET. The video will be simultaneously webcast on www.danaher.com.

Danaher To Present At Goldman Sachs Global Healthcare Conference

WASHINGTON, May 27, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Jefferies Healthcare Conference on Wednesday, June 2, 2021 at 1:00 p.m. ET. The video will be simultaneously webcast on www.danaher.com.

Danaher To Present At Jefferies Healthcare Conference

There's a lot to like about the life sciences and diagnostics company, even after the COVID-19 pandemic.

Is Danaher Stock a Buy?

Total

Danaher's 65-month total return is fantastic, beating the Dow 65-month baseline by 192.88%, an increase from the last quarter. Danaher's last quarter earnings beat expected results by $0.60 on the bottom line, and top-line beat by 58.1%, with an excellent gain over last year's results.

Danaher: Great Total Return, Continues Strong Earnings/Revenue Growth Recovery From The COVID Pandemic

WASHINGTON, May 13, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it has appointed A. Shane Sanders to its Board of Directors and to its Audit Committee.

Danaher Announces Appointment of A. Shane Sanders to Danaher Board

WASHINGTON, May 4, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Healthcare Conference on Tuesday, May 11, 2021 at 2:00 p.m.

Danaher To Present At Bank Of America Healthcare Conference

The life sciences and diagnostics company is a big winner of the COVID-19 pandemic.

Why Danaher Stock Soared in April

The life sciences and diagnostic company is set up for another great year.

Danaher Stock: Buy at the High?

WASHINGTON, April 26, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher"), the global science and technology company, announced today the formation of a Scientific Advisory Board ("Board") to support its innovation and investment strategy. The Board will help the company protect and grow existing scientific innovations, support its development of new technologies and bring unique perspectives to rapidly emerging science and technology trends impacting Danaher.

Danaher Announces Renowned Scientists To Join New Scientific Advisory Board

Danaher Corporation (DHR) CEO Rainer Blair on Q1 2021 Results - Earnings Call Transcript

Danaher's (DHR) first-quarter 2021 revenues increase 57.9% year over year on account of impressive performance across its segments.

Danaher's (DHR) Q1 Earnings & Revenues Surpass Estimates

Danaher (DHR) delivered earnings and revenue surprises of 50.90% and 0.57%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Danaher (DHR) Q1 Earnings and Revenues Surpass Estimates

Shares of Danaher (NYSE:DHR) moved higher by 0.2% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 140.00% year over year to $2.52, which beat the estimate of $1.75.

Recap: Danaher Q1 Earnings

WASHINGTON, April 22, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the first quarter 2021.  All results in this release reflect only continuing operations unless otherwise noted.

Danaher Reports First Quarter 2021 Results

Danaher Corp (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Danaher Corp (DHR)

Danaher's (DHR) Q1 earnings are expected to have gained from strength across its business segments despite the coronavirus outbreak-led issues.

News for Danaher Stock (DHR)